Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News BioLineRx ADS Representing 15 Ord Shs BLRX

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform ,... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:BLRX)

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

PR Newswire 7 days ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

PR Newswire April 10, 2024

BioLineRx Announces $6 Million Registered Direct Offering

PR Newswire April 1, 2024

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

PR Newswire March 26, 2024

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

PR Newswire March 20, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

PR Newswire March 4, 2024

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

PR Newswire February 28, 2024

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

PR Newswire February 16, 2024

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

PR Newswire December 21, 2023

Opinion & Analysis (NDAQ:BLRX)

No current opinion is available.

Bullboard Posts (NDAQ:BLRX)

RE:RE:RE:Entry here

There she goes!!!  Patience pays!!!!
mevani - July 2, 2021

RE:RE:Entry here

Patience pays!
mevani - July 1, 2021

RE:Entry here

I am adding here.   
mevani - May 5, 2021

Dang ......

can't win em all
Iseneschal - May 4, 2021

RE:Entry here

Got to be quick.......taking anything it gives me  No position
Iseneschal - May 4, 2021

Entry here

1 st position
Iseneschal - May 4, 2021